The oncology segment is a core focus for Shanghai Henlius Biotech, driving significant research and development efforts. This segment includes the development and commercialization of biosimilars and innovative biologics targeting various cancer types. Key products include biosimilars of trastuzumab (Hanquyou) for breast and gastric cancer and serplulimab injection (HANSIZHUANG) for various solid tumors. R&D activities focus on novel antibody-drug conjugates (ADCs) and immuno-oncology therapies. The segment aims to improve patient outcomes by providing affordable and effective cancer treatments, leveraging strategic collaborations to expand its global reach and market access. Clinical trials are ongoing to explore new indications and combinations for existing and pipeline products.

Shanghai Henlius Biotech's autoimmune disease segment focuses on developing and commercializing therapies for conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, and uveitis. A key product in this segment is the adalimumab injection (Han Dayuan), a biosimilar of Humira. The company is actively involved in research and development to expand its portfolio of autoimmune disease treatments, exploring new targets and therapeutic modalities. The segment aims to provide patients with accessible and effective treatment options, improving their quality of life and reducing the burden of chronic autoimmune conditions. Clinical trials are conducted to evaluate the safety and efficacy of new therapies and to explore potential combinations with existing treatments.

The ophthalmology segment at Shanghai Henlius Biotech is dedicated to developing innovative treatments for eye diseases, particularly wet age-related macular degeneration (AMD). The company is developing HLX04-O, a bevacizumab injection, as a biosimilar for Avastin, targeting this specific indication. Research and development efforts are focused on improving drug delivery methods and enhancing the efficacy of existing treatments. The segment aims to address the unmet needs of patients with vision-threatening conditions, providing affordable and accessible therapies to prevent vision loss and improve visual outcomes. Clinical trials are underway to evaluate the safety and efficacy of HLX04-O and other potential ophthalmology products.